Hi Pinton,
Found interesting link re development stage valuations, sure every deal is unique on its own merit but interesting view all the same;
In Caraway's case this tool suggest the indications only worth US$3m -$105m each, so premium has been paid it seems given only at preclinical stage.
In Neu's case, start of Phase 2 trail values US$285m and then if successful valuation at the start of Phase 3 trail US$1.2bn, then further upside once FDA approved in Phase 3 trial is completed.
In Neu's case using this tool x 4 indications if successful in Phase 2 could value 2591 at US $4bn-$4.8bn
https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwj63PuZ7dWCAxUCl1YBHRv3CsMQFnoECBwQAQ&url=https%3A%2F%2Fwww.baybridgebio.com%2Fdrug_valuation.html&usg=AOvVaw0v3NC-1jwwtP0fs0bWT8FR&opi=89978449
- Forums
- ASX - By Stock
- NEU
- Merck to acquire Prometheus in a US$ 10.8 b deal
NEU
neuren pharmaceuticals limited
Add to My Watchlist
1.70%
!
$16.76

Merck to acquire Prometheus in a US$ 10.8 b deal, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$16.76 |
Change
0.280(1.70%) |
Mkt cap ! $2.114B |
Open | High | Low | Value | Volume |
$16.65 | $16.84 | $16.33 | $1.103M | 66.08K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 111 | $16.76 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$16.77 | 238 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 77 | 16.770 |
3 | 250 | 16.760 |
4 | 596 | 16.750 |
4 | 224 | 16.740 |
3 | 177 | 16.730 |
Price($) | Vol. | No. |
---|---|---|
16.790 | 62 | 2 |
16.800 | 180 | 5 |
16.810 | 2623 | 7 |
16.820 | 171 | 3 |
16.830 | 128 | 3 |
Last trade - 11.10am 29/07/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |